316 related articles for article (PubMed ID: 9589807)
1. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
2. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
4. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
5. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
8. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
9. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
11. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
16. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
17. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
18. New tumor-associated antigen SC6 in pancreatic cancer.
Liu MP; Guo XZ; Xu JH; Wang D; Li HY; Cui ZM; Zhao JJ; Ren LN
World J Gastroenterol; 2005 Dec; 11(48):7671-5. PubMed ID: 16437697
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
Nouts A; Lévy P; Voitot H; Bernades P
Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
[TBL] [Abstract][Full Text] [Related]
20. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Pålsson B; Masson P; Andrén-Sandberg A
Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
